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ABSTRACT

The present invention pertains to a method of protecting
against neuron loss in a subject by administering a com

pared to Huntington Hippocampus: Correlation With

pound that protects against neuron loss by acting through a
vitamin D receptor. Some of these compounds may prevent

Calbindin—28k mRNA Levels” Molecular Brain Research
13: 239—250.

peripheral calcium and phosphate levels. Other compounds

Musiol, I.M. et al. (1993) “Vitamin D Nuclear Binding to
Neurons of the Alzheimer Pathogenic Region of Nucelus
Basalis of Meynert, Central Amygdaloid Group and Nucleus
of Diagonal Band of Broca” Chemical Abstracts 118(25):
Abstract No. 252564.

or retard neuron loss by regulating intraneuronal and/or
of the invention act through a vitamin D receptor to protect

against neuron loss through mechanisms not involving cal
cium or phosphate regulation. A preferred compound is a
biologically active form of vitamin D, a precursor,
metabolite, or analog of vitamin D. A preferred form of
vitamin D is calcitriol. In another embodiment, the com

Musiol, I.M. et al. (1992) “Vitamin D Nuclear Binding to
Neurons of the Septal, Substritial and Amygdaloid Area in
the Siberian Hamster (Phodopus Sungorus) Brain” Neuro

pound is a compound that acts by modulating the biological

science 48(4):841—848.

biological activity of the vitamin D compound by regulating

Saporito, M.S. et al. (1993) “Pharmacological Induction of

activity of vitamin D, a precursor, metabolite, or analog of
vitamin D. For example, the compound may modulate the

Death in Brain Aging and Alzheimer’s Disease: Role of
Endocrine—Mediated Calcium Dyshomeostasis” J. Neuro

the amount of the vitamin D compound Which is available to
protect against neuron loss or it may act by altering the
ability of the vitamin D compound to protect against neuron
loss. In an alternative embodiment, the compound is a
compound that protects against neuron loss through a
mechanism similar to that of the vitamin D compound but
not involving a vitamin D receptor. The compound is

biol. 23(9):1247—1260.

time effective to protect against neuron loss.

Nerve GroWth Factor mRNA in Adult Rat Brain” Experi

mental Neurology 123(2): 295—302.
Stumpf, W.E. et al. (1982) “Brain Target Sites for 1,25—Di
hydroxyvitamin D3” Science 215(4538): 1403—1405.
Land?eld, P.W. et al. (1992) “Mechanisms of Neuronal

Land?eld, P.W. et al. (1991) “Phosphate/Calcium Aterations
in the First Stages of Alzheimer’s Disease: Implications for
Etiology and Pathogenesis” J. Neurol. Sci. 106:221—229.

administered to a subject in an amount and over a period of

42 Claims, No Drawings
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METHOD OF PROTECTING AGAINST
NEURON LOSS

min D, nor serum calcium differ systematically betWeen

diseased patients and age-matched controls (Shore, D. et al.

(1980) J. Gerontol. 35:656—662; Singh, S. (1988) Age
Ageing 17:21—28; Ferrier, I. N. et al. (1990) Age Ageing

This application is a continuation of copending applica

19:368—375), While a feW have found that some aspects of

tion Ser. No. 08/594,379 ?led on Jan. 30, 1996 Which is a

calcium regulation are altered in diseased patients. Martyn,
C. N. et al. (1989) Gerontology 35:153—157; Ferrier, I. N. et

continuation of application Ser. No. 08/091,976 ?led Jul. 15,
1993 noW abandoned.

al. (1990) AgeAgeing 19:368—375; Ogihara, T. et al. (1990)
Gerontology 36 (Supp. 1): 25—30.

The Work described herein Was supported, in part, by
grants from the United States government.
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BACKGROUND OF THE INVENTION

Unlike many other cell types, neurons cannot be replaced
in the adult brain. Thus, neuron loss in the adult brain has

crippling and generally irreversible consequences Whether it

There have also been studies attempting to ?nd alterations

in peripheral calcium regulating hormones With normal
aging. Some of these studies found changes in calcium
regulation and calcium regulating hormones such as vitamin
D. OrWoll, E. S. and Meier, D. E. (1986) J. Clin. Endocrinol.

and stroke, Which are generally associated With neuron loss
in different regions of the brain. The incidence of many

Metab. 63:1262—1269. HoWever, all of these studies of
peripheral calcium regulation in aging and even in AD have
been correlational, and none has shoWn any causal link
betWeen peripheral calcium regulating hormones and neuron
loss. In fact, none of these studies has even suggested that
vitamin D might affect brain calcium regulation or brain
neuron loss. This is probably due to the generally held belief
that peripheral hormones do not modulate brain calcium

neurodegenerative diseases increases rapidly With aging. For
example, the percent of the individuals beloW age sixty-?ve

vitamin D has not been related to the altered calcium

is caused by age, disease, trauma, or combinations thereof.
The cause of neuron loss during aging is unknoWn. Yet,
there is increasing evidence suggesting that almost everyone

Who lives long enough may succumb to age-related diseases,
such as AlZheimer’s disease (AD), Parkinson’s disease (PD),

Who have AlZheimer’s disease is less than ?ve percent, but
this incidence increases almost exponentially over age sixty

15

20

regulation. Thus, the concept of calcium regulation by
25

?ve, and as many as forty-seven percent of individuals over
eighty-?ve years of age may have some form of AD.

KatZman, R. and Saitoh, T. (1991) FASEB J. 5:278—286;
Evans, D. A. et al. (1989) JAMA 262:2551—2556. Moreover,

homeostasis hypothesis of brain aging.
Thus, the genetic or environmental cause(s) of brain aging
or death of brain neurons, remain largely unde?ned. Clearly,
Whatever the cause, it is the progressive and cumulative
effect of neuron death over a long period of time that results

30

in perceptible physiological changes. Progression of cogni

the brains of essentially all individuals studied over age
eighty contain at least some age- and/or disease-related

studies to be detectable at intervals of no less than one month

neuron loss. Matsuyama, H. et al. (1966) Proceedings of the

to one year. Morris, J. C. et al. (1989) Neurology

tive symptoms due to AD have been found in longitudinal

Fifth International Congress of Neuropathology (Excerpta
Medica International Congress Series No. 100, eds. Luthy, F.
et al.) 979—980. Thus, aging itself is the major risk factor for

39:1159—1165 (Tables 3 and 6). Hippocampal neuron loss
35

due to normal brain aging is even more gradual. Ball, M. J.

(1977) Acta Neuropathol. (Berl.) 37:111—118; Coleman, P.

several types of neurodegenerative diseases, indicating that

D. and Flood, D. G. (1987) Neurobiol. ofAging 8:521—545.

aging increases susceptibility to neuron loss. In fact, there is
much evidence that aging, even in the absence of disease, is
also associated With neuron loss and memory impairment.

Thus, testing over a period of not less than one month, up to
a period of perhaps several years, is necessary to shoW
evidence of reduced neuron loss upon treatment of a subject
With a drug that is purported to be useful in the treatment of
age- or disease-related neurodegeneration.
US. Pat. No. 4,897,388, issued in 1990 on an application
?led in December, 1988 discloses a method of treating

40

Crook, T. et al. (1986) Devel. Neuropsych. 2(4):261—276.
Although the cause of neuron loss in aging and neurode
generative diseases remains unknoWn, one model has been
termed the “altered calcium homeostasis hypothesis”. This
hypothesis is that dysregulated or elevated intracellular

45

patients With AlZheimer’s disease through the administration

calcium levels is a “?nal common pathWay” for many

of a safe and effective amount of a biologically active

neurodegenerative conditions and diseases that eventually

vitamin D3 or D2 material. One patient suffering from

leads to neuron death. It is based to a large extent on

AlZheimer’s disease Was treated With calcitriol for a period

evidence of calcium dysregulation in age-related deteriora

of seven days. The patient’s condition, the symptoms of
Which Were not de?ned, reportedly shoWed improvement.
HoWever, the period over Which testing Was performed is
completely insuf?cient, for the reasons stated above, to shoW
evidence of reduced neuron loss. Additionally, the sample
consisting of a single patient is not large enough from Which
to determine any conclusions, even assuming that the
improvement Was objectively determined. Finally, there is
no explanation of the type of improvement observed but it
is likely to be only the relief of AD symptoms caused by
peripheral effects of the vitamin D material.

tion of the nervous system in animal models of aging.

Khachaturian, Z. S. (1984) Handbook of Studies on Psy

chiatry and Old Age (eds. Kay, D. and BuarroWs, G. D.,
Elsevier, Amsterdam) 7—30; Khachaturian, Z. S. (1989)
Aging 1:17—34; Gibson, G. E. and Peterson, C. (1987)
Neurobiol. Aging 8:329—344; Land?eld, P. W. (1987) Neu

55

robiol Aging 8:346—347. It has also been shoWn that dys
regulated or elevated intracellular calcium can lead to over

activation of enZymes, such as calcium dependent proteases
and endonucleases, that can be toxic to cells. Siesjo, B. K.

(1981) J. Cereb. Blood FlowMetab. 1:155—185; Choi, D. W.
(1987) J Neurosci. 7:369—379.
While aging appears to affect calcium regulation in the

60

brain, investigations of peripheral calcium regulation in
relation to conditions and diseases, for example, AD, a
disease marked by extensive neuron loss, notably in the
hippocampus, generally have been inconsistent. Anumber of
studies have found that neither parathyroid hormone, vita

Loss of neurons from the brain is thought to be a general

characteristic of aging, affecting virtually all of the popula

65

tion. Progressive neuron loss leads, in many circumstances,
to the onset and progression of debilitating neurodegenera
tive diseases, thus presenting a major healthcare burden for
the population. For example, almost $90 billion Was spent in
1991 alone on the treatment of patients With AlZheimer’s

disease. (AlZheimer’s Association, Chicago, Ill.) This is just

5,939,407
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one example of many diseases that may result from neuron

(26—27 months old). FIG. 2A is a photograph of a repre
sentative hippocampal section from ?eld CA1 from an aged

loss. Any remedy Which could treat, or in the optimal case,

prevent, occurrence of age-related neurological diseases by

control rat. FIG. 2B is a photograph of a representative
hippocampal section from ?eld CA1 of an aged rat after 8

preventing neuron loss Would be an immense healthcare
savings as Well as a great improvement in the health outlook

months of calcitriol injections.

for large number of the population. It is therefore imperative
to develop therapies Which can halt or sloW the progression
of neuron loss. Such therapies Would optimally Work over a
long period of time as neuron loss occurs over a long period
of time, and be safe in such time frames With efficacious
dosages. For the foregoing reasons, there remains a critical
need for a method of long term treatment that Will prevent

10

FIGS. 3A and 3B are bar graphs representing the average
number of neurons in the CA1 region of the hippocampus in
100 pm of the CA1 cell layer length for aged male rats
injected over an 8 month period (FIG. 3A—age at initiation
of treatment Was 19—20 months) or a 12 month period (FIG.
3B—age at initiation of treatment Was 9—11 months) With
either calcitriol, calcitonin, or a control substance.

or retard neuron loss in a subject.

SUMMARY OF THE INVENTION

15

The present invention provides a method of protecting a

DETAILED DESCRIPTION OF THE
INVENTION

The present invention makes use of the discovery that a

subject against neuron loss by administering to the subject a

subject may be protected against neuron loss by adminis

compound that protects against neuron loss by acting

tering to the subject a compound Which acts through a
vitamin D receptor to prevent and/or retard neuron loss.

through the vitamin D receptor to prevent or retard neuron
loss. The compound is administered in an amount and over
a period of time effective to protect against neuron loss. In
a preferred embodiment, the period of administration is over

a long term, for example, greater than tWo Weeks and
preferably one month or longer.

Compounds of the present invention protect against neu
ron loss by acting through a vitamin D receptor. Some of

25

Because dysregulated calcium levels have been implicated
in damage to neural tissues, one mechanism through Which
some compounds of the present invention may protect
against neuron loss is by restoring calcium homeostasis.
Other compounds of the present invention act through the
vitamin D receptor to protect against neuron loss Without

regulating calcium levels. Typically, the compound is

these compounds may prevent or retard neuron loss by

administered over a long term and in an amount suf?cient to

regulating intraneuronal and/or peripheral calcium and
phosphate levels. Other compounds of the invention act

protect against neuron loss.
The term “protecting against” is intended to include

through a vitamin D receptor to protect against neuron loss

prevention, retardation, and/or termination of deterioration,

through mechanisms not involving calcium or phosphate
regulation. A preferred compound is a biologically active
form of vitamin D, a precursor, metabolite, or analog of
vitamin D (for ease of discussion beloW, the language
“vitamin D compound” and “vitamin D, a precursor,
metabolite, or analog of vitamin D” Will be used
interchangeably) Which may or may not regulate calcium
and/or phosphate levels. A preferred form of vitamin D is

impairment, or death of a subject’s neurons. The compounds

described herein provide protection against neuron loss.
Neuron loss can be the result of any condition of a neuron
35

rioration can be the result of any condition Which compro
mises neuron function Which is likely to lead to neuron loss.

Neuron function can be compromised by, for example,
altered biochemistry, physiology, or anatomy of a neuron.
Deterioration of a neuron may include membrane, dendritic,
or synaptic changes Which are detrimental to normal neu
ronal functioning. The cause of the neuron deterioration,

calcitriol.

In another embodiment, the compound that is adminis
tered to the subject is a compound that modulates the

biological activity of the vitamin D compound. For example,
the compound may modulate the biological activity of the
vitamin D compound by regulating the amount of endog
enous vitamin D compound Which is available to protect
against neuron loss or it may act by altering the ability of the
vitamin D compound to protect against neuron loss. In an

impairment, and/or death may be unknoWn. Alternatively, it
may be the result of age- and/or disease-related changes
45

Which occur in the nervous system of a subject.
When neuron loss is described herein as “age-related”, it
is intended to include neuron loss resulting from knoWn and

unknoWn bodily changes of a subject Which are associated

alternative embodiment, the compound is a compound that
regulates intraneuronal calcium levels through a mechanism
similar to that of the vitamin D compounds but not involving
a vitamin D receptor (for example, by a post receptor

With aging. When neuron loss is described herein as
“disease-related”, it is intended to include neuron loss result

ing from knoWn and unknoWn bodily changes of a subject
Which are associated With disease. It should be understood,
hoWever, that these terms are not mutually exclusive and

process that modulates intraneuronal calcium levels in a

direction similar to that of vitamin D).
BRIEF DESCRIPTION OF THE DRAWINGS

in Which its normal function is compromised. Neuron dete

that, in fact, many conditions that result in the loss of
55 neurons are both age- and disease-related.

Some of the more common age-related diseases associ

FIGS. 1A, 1B, and 1C represent a schematic depiction of
the method used to section the hippocampus in preparation

ated With neuron loss and changes in neuronal morphology

include, for example, AlZheimer’s disease, Pick’s disease,
Parkinson’s disease, vascular disease, Huntington’s disease,
and Age-Associated Memory Impairment. In AlZheimer’s

for counting CA1 neurons in rats treated With calcitriol,
calcitonin, or a control substance. The elongated hippocam

pus (FIG. 1A) Was dissected free. Blocks of the hippocam
pus Were processed by standard techniques for embedding in
plastic. Thin sections (1 pm thick) Were cut from the block

patients, neuron loss is most notable in the hippocampus,

face (FIG. 1B) and ?eld CA1 neurons Were counted in six

Zones of the hippocampus include the CA1 region, the
subiculum, and the entorhinal cortex. Memory loss is con

sections from each animal (FIG. 1C).
FIGS. 2A and 2B are photographs illustrating density of
the CA1 neurons in sections of hippocampus of aged rats

frontal, parietal, and anterior temporal cortices, amygdala,
and the olfactory system. The most prominently affected
65

sidered the earliest and most representative cognitive change
because the hippocampus is Well knoWn to play a crucial

5,939,407
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role in memory. Pick’s disease is characterized by severe
neuronal degeneration in the neocortex of the frontal and

culture), or other mammalian (See eg US. Pat. No. 5,089,

anterior temporal lobes Which is sometimes accompanied by

models. These inventions have been for protection of periph

death of neurons in the striatum. Parkinson’s disease can be

eral as Well as central nervous system neurons in animal or

identi?ed by the loss of neurons in the substantia nigra and

the locus ceruleus. Huntington’s disease is characteriZed by
degeneration of the intrastriatal and cortical cholinergic

tissue culture models of ischemia, stroke, trauma, nerve
crush, AD, and PD, etc. Neuron deterioration in these model
systems is often proved by experimental trauma or inter

neurons and GABA-ergic neurons. Parkinson’s and Hun

vention (e.g. application of toxins, nerve crush, interruption

tington’s diseases are usually associated With movement

of oxygen supply, etc.). For example, in order to demonstrate
that certain N-methyl-D-aspartate (NMDA), an excitatory

disorders, but often shoW cognitive impairment (memory

517-fetal mouse tissue culture) or non-mammalian animal

10

loss) as Well.

amino acid neurotransmitter receptor, antagonists Were use
ful as anticonvulsants and neuroprotectants, the inventors in
US. Pat. No. 4,957,909 employed a model Wherein SWiss
albino mice and rat hippocampal neurons Were subjected to

Age-Associated Memory Impairment (AAMI) is another
age-associated disorder that is characteriZed by memory loss
in healthy, elderly individuals in the later decades of life.

Crook, T. et al. (1986) Devel. Neuropsych. 2(4):261—276.

15

Presently, the neural basis for AAMI has not been precisely
de?ned. HoWever, neuron death With aging has been
reported to occur in many species in brain regions impli

cated in memory, including cortex, hippocampus, amygdala,
basal ganglia, cholinergic basal forebrain, locus ceruleus,
raphe nuclei, and cerebellum. Crook, T. et al. (1986) Devel.

20

Neuropsych. 2(4):261—276.
Subjects Who can be treated by the method of this

study Was performed Wherein the utility of certain NMDA
antagonists as agents that prevent neurodegeneration Was
demonstrated by treating mice With NMDA subsequent to
treatment With the NMDA antagonists. US. Pat. No. 5,168,
103. Another experimental model Wherein the inventors, in
order to demonstrate the ability of indolactam V compounds
to prevent destruction of neocortical neurons, exposed in
vitro cultures of fetal mouse neurons and glial cells to

invention include living organisms, e.g. mammals, suscep
tible to age- and/or disease-related neuron loss. Examples of

overstimulation of excitatory amino acid receptors subse
quent to treatment With the NMDA antagonists. A similar

25

various glutamate agonists, such as kainate, NMDA, and

subjects include humans, dogs, cats, rats, and mice. Lower

ot-amino-3-hydroxy-5-methyl-4-isoxaZolepronate (AMPA).

mammal models using, for example, rats or mice can be used

US. Pat. No. 5,089,517. See also US. Pat. No. 5,170,109
(treatment of rat cortical/hippocampal neuron cultures With

to predict modes of general brain aging and associated
neuron loss in higher mammals, such as humans.

Aging rodent brains do not develop senile plaques and
neuro?brillary tangles. Most recent studies suggest,
hoWever, that loss or shrinkage of neurons, dendrites, and/or

30

improvement in the model for age-associated neuroprotec
35

40

11:1316—1324) as Well as cell loss or dendritic/synaptic

changes in some other brain regions. Coleman, P. D. and

Flood, D. G. (1987) Neurobiol. Aging 8:521—545;

(neuroprotective excitatory amino acid receptor antagonists
inhibit glycine, kainate, AMPA receptor binding in rats).
HoWever, the present animal model represents an

synapses is more closely correlated With either dementia or

aging than are plaques and tangles. Terry, R. D. et al. (1987)
Ann. Neurol. 21:530—539; Terry, R. D. et al. (1990) J.
Neuropathol. Exp. Neurol. 491335; Buell, S. J. and Coleman,
P. D. (1981) Brain Res. 214:23—41; Scheff, S. W. et al.
(1990) Neurobiol. Aging 11:29—37. Aging rats exhibit neu
ronal cell loss in the pyramidal cells of the hippocampus,
especially in ?eld CA1, (Land?eld, P. W. et al. (1981)
Science 214:581—584; Land?eld, P. W. (1987) Prog. Brain
Res. 72:279—300; Kerr, D. S. et al. (1991) J. Neurosci.

glutamate prior to treatment With neuroprotective
compound); US. Pat. Nos. 5,163,196 and 5,196,421

45

tion because it relates to an intact animal, Which is generally
preferred over tissue culture models, and employs a strain of
rat that Was developed by the National Institute on Aging as
a premier model of mammalian aging. The particular rat
strain (BroWn NorWay/Fischer 344 F1 cross rats) Was
selected as such a model due to its normal pattern of aging,
With feW indications of abnormal pathology. This strain also
loses neurons in ?eld CA1 of the hippocampus With aging
and exhibits memory loss. This system represents one of the
most natural animal models of neuron degeneration and/or
deterioration because it re?ects a gradual loss of neurons.

Furthermore, the neuron loss is not provoked by experimen
tal intervention or abnormal pathology. Its brain aging
pattern is also highly analogous to human and other mam

Geinisman, Y. et al. (1986) Brain Res. 398:266—275.
Moreover, aging rodents shoW extensive hippocampal astro

cyte hypertrophy (Land?eld, P. W. et al. (1977) J. Gerontol.
32:3—12; Land?eld, P. W. et al. (1978) Science
202:1098—1102; Geinisman, Y. et al. (1978) Am. J. Anat.
153:537—544) just as do aging humans. WisnieWski, H. M.
and Terry, R. D. (1973) Progress in Brain Research (ed.

malian species’ brain aging patterns.
The compound is administered through a route Which
alloWs the compound to perform its intended function of
protecting against neuron loss in a subject. Examples of

Ford, D. M. Elsevier, Amsterdam) 40:167—186; Hansen, L.

routes of administration Which may be used in this method

A. et al. (1987) Neurobiol. Aging 8:1—6. In addition, loss of

include parenteral (subcutaneous, intravenous,
intramuscular, intraarterial, intraperitoneal, intrathecal,

neurons in ?eld CA1 of the hippocampus is a consistent 55

correlate of aging across species, and is also prominent in
human neurodegenerative diseases, such as AD. For these
reasons, the study of neuron loss in aging rats, for example,
is predictive of general mechanisms of brain aging and
associated neuron loss in humans.

intracardiac, and intrasternal), enteral administration (i.e.
administration via the digestive tract), mucosal
administration, and percutaneous administration. Depending
on the route of administration, the compound may be coated
60

Which may detrimentally affect its ability to perform its
intended function. A particularly convenient method of
administering a compound of the present invention, for
example a vitamin D compound, is percutaneous adminis

Because of the great dif?culty associated With measuring
brain neuron loss in living humans or even in autopsy

material, Which is highly variable and often shoWs massive
changes due to the postmortem interval prior to ?xation,
many neuroprotective inventions have been based on in vitro
tissue culture systems of neurons from embryonic rodent
pups (See eg US. Pat. No. 5,179,109-fetal rat tissue

With or in a material to protect it from the natural conditions

65

tration.

The administration of the compound is performed in
accordance With the invention, at dosages and for periods of
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time effective to protect against the loss of neurons in a

mechanism of action Which is similar to those of other

subject. Dosage regimes may be adjusted for purposes of
improving the therapeutic response to the compound. For

steroid hormones. The language “vitamin D, precursor,
metabolite, or analog of vitamin D” is intended to include
vitamin D or an analog thereof, in any stage of its metabo
lism. This language is also intended to include mixtures of

example, several divided doses may be administered daily or
the dose may be proportionally reduced as indicated by the

exigencies of the therapeutic situation.
Compounds of the present invention protect against neu

different metabolic forms of vitamin D or a vitamin D

ron loss by acting through a vitamin D receptor. Vitamin D
receptors are Well knoWn to exist in the periphery but have

calcium homeostasis by interfering With mechanisms Which
result in neurotoxic levels of calcium and/or phosphate.
Alternatively, the vitamin D compounds may protect against

also been found in the brain, particularly in the hippocampus

analog. The vitamin D compounds may preserve or restore

10

and neocortex. Some of these compounds may prevent or

retard neuron loss by regulating intraneuronal and/or periph
eral calcium and phosphate levels. Other compounds of the

skin by ultraviolet irradiation (D3 or cholecalciferol).

invention act through a vitamin D receptor to protect against
neuron loss through mechanisms not involving calcium or

phosphate regulation. The compounds that act by regulating

15

calcium and/or phosphate levels modulate calcium and/or
phosphate homeostasis of either peripheral or intraneuronal
20

loss.
One Way a compound can protect against neuron loss by

acting through the vitamin D receptor is by modulating the
biological activity of a vitamin D compound. This can be

done by modulating the amount of the vitamin D compound
that is available to protect against neuron loss. Generally, the
compound Will increase the amount of vitamin D compound
that is available to protect against neuron loss by increasing
the synthesis or expression of the vitamin D compound. For

example, the biphosphonate YM175 (methylene-1,1

25

30

of 1,25 dihydroxy-vitamin D by stimulating renal
1-hydroxylase activity in rats. Nagao, Y. et al. (November
1991) Biochem. Biophys. Res. Comm. 180(3): 1172—1178.
35

calcitriol Which is believed to be one of the most active

metabolites of vitamin D. Another biphosphonate, HPeBP
(1-hydroxypentane-1,1-biphosphonate), has been shoWn to

induce stimulation of 1,25 dihydroxy-vitamin D. Bonjour,
J .-P. et al. (1988) Am. J. Physiol. 254:E260—E264. Vitamin
D receptor agonists also contribute to the regulation of the
amount of the vitamin D compound that is available to
protect against neuron loss.
Another Way in Which a compound of the present inven
tion can protect against neuron loss by acting through a
vitamin D receptor is by altering the ability of the vitamin D
compound to protect against neuron loss. Such compounds

40

45

to be one of the most active forms of vitamin D3. It is
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(CALCIJEX®, Abbott Laboratories, Inc.).
The term “biologically active” is intended to include an

activity for the vitamin D, precursor, metabolite, or analog
of vitamin D, Which alloWs it to perform its intended
function. It is knoWn in the art that vitamin D compounds
60

droepiandrosterone (DHEA).
In a preferred embodiment, the compound is a biologi
cally active form of vitamin D, or a precursor, metabolite, or
analog of vitamin D. Vitamin D is generally classi?ed as a

molecular modi?cation to yield active metabolites, and its

10., 24-dihydroxy-25-?uoro-7-dehydrocholesterol (10., 24

(OH)2-25F proD3), 25,26-dihydroxy-7-dehydrocholesterol
(25 ,26-(OH)2 proD3), 25-hydroxy-7-dehydrocholesterol
(25-OH proD3), 25-hydroxy ergosterol (25-OH proD2), 10.,
25-dihydroxy ergosterol (10., 25-(OH)2 proD2), 10.,
25-dihydroxy precholecalciferol (10., 25-(OH)2 preD3), 10.,
24,25-trihydroxy precholecalciferol (10., 24, 25-(OH)3
preD3), 24,25-dihydroxy precholecalciferol (24,25-(OH)2
preD3), 1ot-hydroxy precholecalciferol (lot-OH preD3), 10.,
24-dihydroxy-25-?uoro-precholecalciferol (10., 24-(OH)2
25F preD3), 25-hydroxy-precholecalciferol (25-OH preD3),
1ot-hydroxy-previtamin D2 (lot-OH preD2), 25-hydroxy

presently commercially available in capsule form
(ROCALTROL®, Roche Laboratories) or in injection form

Such compounds include, for example, glucocorticoid

steroid hormone because of its hormonelike relationship

metabolites include, for example, 1ot25-dihydroxy-B

7-dehydrocholesterol (10., 25-(OH)2 proD3), 10., 24,25
trihydroxy-7-dehydrocholesterol (10., 24,25-(OH)3 proD3),
24,25-dihydroxy-7-dehydrocholesterol (24,25-(OH)2
proD3), 10t-hydroxy-7-dehydrocholesterol (lot-OH proD3),

A vitamin D3 metabolite Which is particularly useful in
the method of the present invention is 1,25 dihydroxychole
calciferol (1,25 (OH)2-D3 or calcitriol). Calcitriol is believed

regulate, directly or indirectly, calcium and/or phosphate

With calcium and phosphate metabolism, its pathWay of

(OH)2 25 -FD3), 25 -hydroxy cholecalciferol (25-OHD3), and
1ot-hydroxy cholecalciferol (1ot-OHD3).

previtamin D2 (10., 25-(OH)2 preD2).

vitamin D compound. There are still other neuroprotective
compounds, such as other steroids or related compounds,
Which may not act through the vitamin D receptor but may

receptor antagonists such as mifepristone, mifepristone
derivatives (See eg U.S. Pat. No. 4,386,085), and dehy

1ot-hydroxy ergocalciferol (1ot-OHD2), 25-hydroxy ergocal
ciferol (25-OHD2), 10., 25-dihydroxy ergocalciferol (10.,
25-(OH)2D2), 10., 25-dihydroxy cholecalciferol (10., 25
(OH)2D3), 10., 24, 25-trihydroxy cholecalciferol (10., 24,
25-(OH)3D3), 24,25-dihydroxy cholecalciferol (24,25-(OH)
2D3), 10., 24-dihydroxy-25-?uoro cholecalciferol (10., 24

previtamin D2 (25-OH preD2), and 10., 25-dihydroxy

include binding proteins, such as vitamin D-binding protein.
These proteins may act by increasing the stability of the

levels in a manner similar to that of vitamin D (for example,
by a post receptor process that modulates intraneuronal
calcium levels in a direction similar to that of vitamin D).

ergocalciferol). D2 and D3 have identical biological actions.
Vitamin D2 and D3 compounds include, for example,

Vitamin D2 and D3 precursors and metabolites are also
biologically active. Vitamin D2 or D3 precursors and

biphosphonate) has been found to stimulate renal production

Renal 1-hydroxylase is an enZyme that hydroxylates 25
dihydroxy vitamin D to yield 1,25 dihydroxy vitamin D, or

Another source is vitamin D ingested in the diet (D2 or

dihydrotachysterol2, dihydrotachysterol3, 5,6-trans
cholecalciferol, 25-hydroxy-5,6-trans cholecalciferol,

calcium and/or phosphate or restore dysregulated calcium to

normal levels, thereby providing protection against neuron

neuron loss through mechanisms not involving calcium
regulation. Generally, there are tWo sources of vitamin D in
most mammals. One source is vitamin D produced in the
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display varying degrees of activity and it is contemplated
that any of the biologically active forms of vitamin D can be
used in the method of this invention.
The compound is administered over a period of time
effective to protect against neuron loss in a subject.
Typically, the treatment period Will be over a long term. The
phrase “long term,” as used herein is a time period of such
a duration that a subject treated With the compound, When

5,939,407
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compared With a subject not so treated, is protected against

group of rats received subcutaneous injections of calcitriol
daily at the rate of 20 ng/rat/day for ?ve consecutive days
per Week. For the 18—19 month old rats, the injections
continued for a period of 8 months. For the 9—11 month old
rats, the injections continued for a period of 12 months.

neuron loss. Generally, changes in neuron number are not

apparent until at least approximately tWo Weeks into the
treatment. Thus, “long term” administration of the com
pound refers to a period of administration of greater than tWo

Weeks, and usually about one month, or longer. Preferably,

Salmon calcitonin Was obtained from either Bachem

the administration is over a period of time from about six

(Torrance, Calif.) or Calbiochem (San Diego, Calif.) in 1 mg
vials. The peptide Was kept in aliquot form in light-free

months to one year or longer.

An amount of the compound Which is effective to protect
against neuron loss in a subject is the amount of compound

conditions in a —40° C. freeZer and diluted daily for injec
10

tion. The diluant consisted of a ?ltered and autoclaved

solution of the folloWing components: 20 mg polysorbate,
45 mg NaCl, 300 mg ascorbic acid, 228 mg dibasic phos

sufficient to prevent, retard, and/or terminate deterioration,
impairment, and/or death of a neuron. The dose of the

phate buffer, 54 mg monophosphate buffer, and 30 mg

compound suf?cient to protect against neuron loss is depen
dent both on the speci?c activity of the compound and its

EDTA. This diluant Was used in order to match the vehicle
concentration. Choice of an appropriate dose can be deter 15 in Which calcitriol is commercially available. A second
group of rats received subcutaneous injections at a dose of
mined on an individual basis and Will be based, at least in

part, on consideration of the severity of the symptoms to be

2 IU/rat/day (?ve days/Week) of calcitonin. A control group

treated and the activity of the speci?c compound used.

of rats received subcutaneous injections of a control solution
consisting of the same ingredients in the same amounts as
the CALCIJEX® solutions, minus the calcitriol or
calcitonin, at the same rate. For the 18—19 month old rats, the

Further, the effective amounts of the compound may vary
according to the age, sex, and Weight of the subject being

20

treated. Thus, an effective amount of the compound can be

determined by one of ordinary skill in the art employing
such factors as described above using no more than routine

experimentation.
The invention is further illustrated by the folloWing
non-limiting examples. The contents of all references and
issued patents cited throughout this application are expressly

25

In order to assure that the drugs Were biologically active
and to determine that there Were no toxic side effects

produced by the drugs, the animals that Were used for
hippocampal cell density measurements in the 8 month

incorporated herein by reference.
EXAMPLES
Animals
The rats used in this experiment Were male BroWn Nor

30

vacutainer, for blood collection.

Tissue Preparation
35

tained in a largely germ-free (speci?c pathogen free) envi
ronment and have a mean longevity When maintained in
such a controlled environment of about 29—30 months of

age. The animals continued to be maintained, throughout the
injection period, in laminar air ?oW ?lter barriers in animal
facilities and fed, ad libitum, a diet of rodent choW and

40

and pathologies Were noted.
Animals Were kept on six foot animal racks and each drug
group had the same number of animals in every position at
the start of the study. Positioning the rats in order to equaliZe
the amount of light to Which they Were exposed Was impor
tant because serum vitamin D levels can be in?uenced by the
amount of light that the rats received.

Three groups, each consisting of betWeen eight and thir

Upon completion of both the 8 and 12 month injection
periods, the animals in the calcitriol-treated, calcitonin
treated and control-treated groups Were injected With a lethal
dose of sodium pentobarbital. The animals Were alloWed to
reach a deep level of anesthesia before the perfusion Was
initiated. Blood Was taken from the left ventricle just prior

to the perfusion by the ?xative. Table I illustrates the effects

Water. Animals Were Weighed Weekly to monitor any effect
of the drugs on their body Weight and health. Food and Water
study Was done during the ?rst months to monitor effect of

drugs on their food consumption. All animals that displayed
any physical health problems Were necropsied and blood
Was taken for analysis. During necropsy, organ condition

injection study also had blood analysis tests done. (Table I)
Blood Was collected after the injection of sodium pentobar
bital and just prior to intracardial perfusion, using a

Way x Fischer 344 F1 cross hybrid rats Which Were obtained

from the National Center for Toxicology Research
(Jefferson, Ark.). These F1 cross hybrid rats Were main

injections of calcitonin and the control substance continued
for a period of 8 months. For the 9—11 month old rats, the
injections of calcitonin and the control substance continued
for a period of 12 months.

of calcitriol and calcitonin on the levels of calcium in the
blood of the rats Which Were 18—19 months old at the

initiation of the injections after 8 months of injections. As
45

Was expected, calcitriol treatment resulted in a signi?cantly
increased level of blood calcium and phosphorous over that
in the blood of controls. Calcitonin treatment resulted in

blood calcium levels slightly but not signi?cantly above that
50

found in the blood of controls. Data shoWn are
means:S.E.M.

TABLE I
BLOOD SUMMARY FOR BROWN NORWAY X F344
RATS AFTER 8 MONTHS OF INJECTION

55

teen rats, Were carefully selected and matched for age and

Control

Calcitriol

Calcitonin

Body Weight

574.4 1

529.2 +

559.7 1

14.93

body Weight at the start of each study. In the ?rst study, rats
betWeen 18 and 19 months of age Were subjected to drug
injections for a period of 8 months. At the end of the
injection period, the rats Were betWeen 26 and 27 months
old. In the second study, rats betWeen 9 to 11 months of age
Were subjected to drug injections for a period of 12 months.
At the end of the injection period, the rats Were betWeen 21
and 23 months old.

Drugs
Calcitriol (CALCIJEX®, in 2 mg/ml vials, Was obtained
from Abbott Laboratories, Inc (Abbott Park, 111.). A test

60

(p = 0.2171)

26.9

13.11

Sodium

144.6 1

146.2 +

146.4 1

(p = 0.2831)

1.32

0.48

0.62

Potassium

5.15 r

5.46 r

5.13 r

(p = 0.5890)

.328

0 272

0.195

Chloride

100.73 1

98.42 1

93.60 1

(p = 0.5403)

1.01

0.489

6.966

C02

29.00 1

29.75 1

29.66 1

0.735

0 657

0.744

19.91 1

15.92 1

18.86 1

65 (p = 0.7400)
Urea
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neuron starting in one photograph but not in the other

adjacent section of the pair Were counted for each animal.

TABLE I-continued

This is a neW stereological method that provides a reliable
index of number of neurons in a section, Which is unbiased

BLOOD SUMMARY FOR BROWN NORWAY X F344
RATS AFTER 8 MONTHS OF INJECTION

Control

Calcitriol

Calcitonin
2.595

(p = 0.3365)

1.237

0.983

Glucose

168.82 1

183.75 1

166.20 1

(p = 0.4467)

14.100

8.776

9.643

Calcium

10.282 1

11.10** 1

10.314 1

(p = 0.0003)M

.13772

.13236

.16127

Phosphorus

4.336 r

4.842** r

4.100 r

(p = 0.0065)M

.15954

0.1727

0.1607

Creatinine

0.555 1

0.4667 1

0.5933 1

by shape or size of the neurons. Pakkenberg, B. and

10

Gundersen, H. J. G. (1989) APMIS 97:677—681; West, M.
and Gunderson, H. (1990) J. Comp. Neurol. 296:1—22. The
length of the cell layer in each section Was measured using
a calibrated imaging system (Sigma Scan) and the average
number of CA1 neurons/ 100 pm of the CA1 cell layer length

(p = 0.0963)

0.0389

0.02346

0.0529

Was obtained. FIGS. 2A and 2B shoW photographs illustrat
ing CA1 neurons in the hippocampus of rats between the
ages of 26—27 months after they have been injected over an
8 month period With a control substance (FIG. 2A) or

Uric Acid

0.6545 1

0.9833 1

0.9600 1

calcitriol (FIG. 2B). After the injection period, the hippoc

(p = 0.5229)

0.2471

0.2219

0.2077

ampal tissue Was embedded, sectioned (1 pm), and stained

Cholesterol

101.727 1

90.250 1

89.733 1

4.516

With Toluidine Blue. After calcitriol treatment (FIG. 2B), a
greater density of neurons appears in the hippocampal
section. After treatment With the control substance (FIG.
2A), there are gaps and empty regions Where the hippoc
ampal neurons have died.
The average number of CA1 neurons/ 100 pm of the CA1

(p = 0.1464)

5.0737

4.814

Protein

6.100 1

6.2250 1

6.0467 1

(p = 0.6626)

0.1697

0.0814

0.1653

Albumin

2.918 1

3.0500 1

2.8733 1

0.127

(p = 0.5839)

0.1902

0.302

Total Bilirubin

0.200 r

0.208 r

0.213 r

(p = 0.9095)

0.245

0.0239

0.0199

Alkaline

127.636 1

99.00 1

87.333 1

cell layer length for the calcitriol, calcitonin, and control

(p = 0.1386)

27.47

5.5402

6.9324

Glut. Oxaloacetic Transaminase

116.091 1

103.167 1

110.987 1

groups for both experiments is shoWn in FIGS. 3A and 3B.
FIGS. 3A and 3B shoW bar graphs illustrating the number of
CA1 neurons/100 pm of the CA1 cell layer length in

(p = 0.8486)

15.653

17.779

14.398

Lactate Dehydrogenase

277.818 1

284.00 1

377.600 1

(p = 0.5820)

74.7116

70.393

87.925

hippocampal sections of calcitriol-treated, calcitonin

Iron

171.546 1

195.083 1

187.533 1

24.778

treated, and control-treated rats after 8 and 12 months of
injections. Rats of tWo different age groups Were used, the

(p = 0.766)

26.899

13.266

Magnesium

1.813 r

1.725 1

1.7091 1

(p = 0.4625)

0.0426

0.0670

0.0574

Corticosterone

302.143 1

280.273 1

283.364 1

(p = NS)

55.019

32.364

48.163

30

group treated for 8 months being substantially older (18—19
months) than the group treated for one year (9—11 months)
at the start of the study. Neuron loss in the rats that Were

treated With calcitriol Was prevented, inhibited, and/or
retarded as compared to the rats treated With the control

Subsequently, the animals Were perfused With a 2%

glutaraldehyde-2% paraformaldehyde ?xative solution at 4°

35

C. for 30 minutes. After perfusion Was completed, the brain
of each animal Was dissected and placed in the 2%

glutaraldehyde-2% paraformaldehyde ?xative overnight at
4° C.
The frontal lobes and cerebellum Were dissected aWay and
the remaining hippocampus and cortex Were cut in 250 pm
thick sections starting at the most anterior portion of the

40

hippocampus. The resulting sections Were collected serially
45

average number of CA1 neurons/100 pm in the control
group Was about 1.2. The calcitonin-treated group of rats had

among the three groups of animals.

the loWest average number of CA1 neurons/100 pm With
about 1.1 CA1 neurons/100 pm. These results clearly dem
onstrate that long term treatment With calcitriol prevents
and/or retards neuron loss in aging rats.

Light Microscopy
The 250 pm-thick sections Were processed as indicated by
the standard embedding for electron microscopy or for

“semithin” sections used in light microscopy. Peters, A. and
Palay, S. L., The Fine Structure of the Nervous System
(Harper & RoW, NeW York 1970); Land?eld, P. W. et al.
(1981) Neurobiol. Aging 2:265—275. Blocks Were in?ltrated
With Epon 812 from Ted Pella (Redding, Calif.).
After embedding, 1 pm-thick semithin sections containing

control group Was about 1.4. The calcitonin-treated group of
rats had the loWest average number of CA1 neurons/100 pm
With about 1.3 CA1 neurons/100 pm.
The average number of CA1 neurons/ 100 pm of the CA1

cell layer length in the hippocampal sections of the 8 month
(FIG. 3B) calcitriol-treated group Was about 1.4, While the

into sodium cacodylate buffer. The section that Was 2250 pm

posterior in the ?rst experiment and 1750 pm posterior in the
second experiment Was consistently used for comparison

injection. The average number of CA1 neurons/100 pm of
the CA1 cell layer length in the hippocampal sections of the
12 month (FIG. 3A) calcitriol-treated group Was about 1.65,
While the average number of CA1 neurons/100 pm in the

Equivalents
Those skilled in the art Will recognize, or be able to
ascertain using no more than routine experimentation, many

equivalents to the speci?c embodiments of the invention
55

described herein. Such equivalents are intended to be

at least several hundred pm of the CA1 neuron layer Were

encompassed by the folloWing claims.

cut from the face of the 250 pm-thick section. (See FIGS.
1A, 1B, and 1C) The ?rst ?ve Wells of a glass slide Were
?lled With adjacent semithin sections and then the next 50

I claim:
1. Amethod for protecting against neuron loss in a subject
affected With neuron loss resulting from a neurodegenerative

pm of the section block Was discarded. Then ?ve additional
semithin sections Were cut serially into another ?ve Wells.

condition, comprising:
(a) providing a compound Which protects against neuron
loss by acting through a vitamin D receptor; and
(b) administering the compound to the subject in an

Discarding the intervening 50 pm alloWed for sampling of a
larger region of the hippocampus. Semithin sections Were
then stained With Toluidine Blue and coverslipped for analy
sis.

For each animal, three pairs of the adjacent sections Were
photographed. The cells that had the beginning “top” of one

65

effective amount and over an effective period of time,
so as to provide protection against neuron loss.

2. The method of claim 1 Wherein the compound is
administered over a long term.

5,939,407
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3. The method of claim 2 wherein the period of admin
istration is about siX months or longer.
4. The method of claim 1 Wherein the compound regulates
intraneuronal calcium levels.
5. The method of claim 1 Wherein the compound regulates

22. The method of claim 20 Wherein the compound alters
the ability of vitamin D, or a precursor or metabolite of

vitamin D, to protect against neuron loss.
23. A method according to claim 1, Wherein the subject is
other than a patient suffering from AlZheimer’s disease.
24. A method according to claim 1, Wherein the neuro
degenerative condition is AlZheimer’s disease.
25. Amethod of protecting against neuron loss in a subject
affected With neuron loss resulting from a neurodegenerative

peripheral calcium levels.
6. The method of claim 2, Wherein the period of admin
istration is about 1 month or longer.

7. The method of claim 1 Wherein the compound regulates

peripheral phosphate levels.

10

8. The method of claim 1 Wherein the compound regulates
intraneuronal phosphate levels.

age-related.
15

29. The method of claim 25, Wherein the period of
25

31. The method of claim 25, Wherein the compound is

32. The method of claim 25, Wherein the neurodegenera
tive condition is selected from the group consisting of

enterally administered to the subject.

AlZheimer’s disease, Pick’s disease, Parkinson’s disease,

17. The method of claim 1 Wherein the compound is a

Vascular Disease, Age Associated Memory Impairment,
Stroke, Huntington’s disease.
35

33. A method according to claim 25, Wherein the neuro

degenerative condition is AlZheimer’s disease.
34. A method according to claim 33, Wherein the neuro

degenerative condition is AlZheimer’s disease.
35. A method of protecting against neuron loss in a

subject, comprising:
(a) providing a biologically active form of a steroid, or
metabolite or analog of a steroid Which protects against
neuron loss through a mechanism similar to that of

vitamin D but not acting through the vitamin D recep
tor; and

(b) administering the biologically active form to the
subject in an amount and over a period of time,
determined to be effective Without reference to provid
ing acute alleviation of symptoms in the subject, so as

to provide protection against neuron loss, such protec
tion being independent of any acute alleviation of such

symptoms.
36. A method of protecting against neuron loss in a

subject, comprising:
55

(a) providing a compound other than vitamin D2 or

vitamin D3, their corresponding previtamins and
provitamins, metabolites and analogues, capable of
acting through a vitamin D receptor; and

19. The method of claim 18 Wherein the vitamin D
metabolite is calcitriol.
20. The method of claim 1 Wherein the compound modu
lates the biological activity of vitamin D, a precursor,
metabolite, or analog of vitamin D, in a manner effective to
protect against neuron loss.
21. The method of claim 20 Wherein the compound

neuron loss.

30. The method of claim 29, Wherein the period of
administered over a long term.

16. The method of claim 1 Wherein the compound is

regulates the amount of the vitamin D, precursor, metabolite,
or analog of vitamin D, Which is available to protect against

administration is about one month or longer.

administration is about siX months or longer.

parenterally administered to the subject.

dihydrotachysterol3, 5,6-trans-cholecalciferol, 25-hydroXy
5,6-trans cholecalciferol, lot-hydroxy ergocalciferol,
25-hydroXy ergocalciferol, 10., 25-dihydroXy ergocalciferol,
10., 25-dihydroXy cholecalciferol, 10., 24, 25-trihydroXy
cholecalciferol, 24,25-dihydroXy cholecalciferol, 10.,
24-dihydroXy-25-?uoro cholecalciferol, 25-hydroXy
cholecalciferol, lot-hydroxy cholecalciferol, 10.,
25-dihydroXy-B 7-dehydrocholesterol, 10., 24,25
trihydroXy-7-dehydrocholesterol, 24,25-dihydroXy-7
dehydrocholesterol, 1ot-hydroXy-7-dehydrocholesterol, 10.,
24-dihydroXy-25-?uoro-7-dehydrocholesterol, 25,26
dihydroXy-7-dehydrocholesterol, 25-hydroXy-7
dehydrocholesterol, 25-hydroXy ergosterol, 10.,
25-dihydroXy ergosterol, 10., 25-dihydroXy
precholecalciferol, 10., 24,25-trihydroXy precholecalciferol,
24,25-dihydroXy precholecalciferol, lot-hydroxy
precholecalciferol, 10., 24-dihydroXy-25-?uoro
precholecalciferol, 25-hydroXy-precholecalciferol,
1ot-hydroXy-previtamin D2, 25-hydroXy-previtamin D2, and
10., 25-dihydroXy-previtamin D2.

determined to be effective to provide protection against
neuron loss.

AlZheimer’s disease, Pick’s disease, Parkinson’s disease,
Vascular Disease, Stroke, Age Associated Memory
Impairment, and Huntington’s disease.

biologically active form of vitamin D, a precursor,
metabolite, or analog of vitamin D.
18. The method of claim 17 Wherein the vitamin D,
precursor, metabolite, or analog of vitamin D, is selected
from the group consisting of dihydrotachysterol2,

D, a precursor, metabolite, or analog of vitamin D to the
subject in an amount and over a period of time,

26. The method of claim 25 Wherein the subject is a
mammal.
27. The method of claim 26 Wherein the mammal is a
human.
28. The method of claim 25 Wherein the vitamin D
metabolite is calcitriol.

12. The method of claim 1, Wherein the neurodegenera
tive condition is selected from the group consisting of

13. The method of claim 1 Wherein the subject is a
mammal.
14. The method of claim 13 Wherein the mammal is a
human.
15. The method of claim 1 Wherein the compound is

(a) providing a biologically active form of vitamin D, a
precursor, metabolite or analog of vitamin D; and

(b) administering the biologically active form of vitamin

9. The method of claim 1 Wherein the neuron loss is
10. The method of claim 1 Wherein the neuron loss is
disease-related.
11. The method of claim 1 Wherein the neuron loss is age
and disease-related.

condition, comprising:

(b) administering the compound in an amount and over a
period of time, determined to be effective so as to

provide protection against neuron loss.
37. Amethod of protecting against neuron loss in a subject
at increased risk of neurological impairment by reason of at
least one of aging and disease, other than AlZheimer’s
65

disease, comprising:
(a) providing a biologically active form of vitamin D, a
precursor, metabolite or analog of vitamin D; and
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(b) administering the biologically active form of vitamin

40. A method according to claim 39, Wherein the subject
is suffering from a neurological disease.
41. A method according to claim 40, Wherein the subject
is suffering from a neurological disease other than AlZhe

D, a precursor, metabolite, or analog of vitamin D to the
subject in an amount and over a period of time,

determined to be effective to provide protection against

imer’s disease.
42. A method for protecting a brain affected With neuron

neuron loss.

38. A method of protecting the brain of a subject against
neuron loss, comprising:

loss resulting from a neurodegenerative condition, compris

ing:

(a) providing a compound capable of acting through a
vitamin D receptor; and

(b) administering the compound to the subject in an
effective amount and over an effective period of time,
so as to provide protection against neuron loss.

39. A method according to claim 38, Wherein the subject
has an increased risk of neurological impairment by reason
of at least one of aging and disease.

10

(a) providing a compound Which protects against neuron
loss by acting through a vitamin D receptor; and
(b) administering the compound to the brain in an effec
tive amount and over an effective period of time, so as

to provide protection against neuron loss.
*

*

*

*

*
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